Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluriad
- Development stage
- Unknown
- Lead developer
- Vectans Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Buccal
01
Overview
Fluriad is an investigational buccal vaccine candidate being developed by Vectans Pharma for the prevention of influenza and potentially other respiratory infections. It utilizes the company's proprietary Lauriad technology, a muco-adhesive buccal tablet platform that adheres to the gum to deliver active ingredients through the oral mucosa. This needle-free approach is designed to induce both systemic and mucosal immunity, providing a non-invasive alternative to traditional injectable vaccines. Fluriad is currently in Phase 2/3 clinical development, with some sources indicating it has reached Phase 3.
- Brand names
- Fluriad
02
Targets
NeuraminidaseCYP3A4 (Cytochrome P450 3A4)HA (Hemagglutinin)
Beyond the preview
Go deeper on Fluriad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fluriad.